Cancer Therapy AdvisorPhytochemical-Rich Food & Probiotic Supplements Appear to Slow Progression in Low-Risk Prostate Cancer

This UK phase 2 RCT (n=208) demonstrates that phytochemical-rich food supplementation combined with Lactobacillus probiotics significantly slowed PSA progression in men with low-risk prostate cancer on active surveillance, with the probiotic arm showing 44.6% reduction in PSA progression versus 13.1% with phytochemicals alone. The trial provides evidence for potential dietary interventions that may help men remain on active surveillance longer, though findings are specific to these formulations and require validation in larger trials.

🔬 Key Clinical Considerations

• PSA progression slowed significantly in both arms, with phytochemical-only supplementation reducing progression from 19.6% to 6.5% over 4 months, while adding probiotics produced a 44.6% change (23.2% to -21.4% progression rate).
• Inflammatory marker improvements occurred only with probiotic addition, as neutrophil-to-lymphocyte ratio decreased by 0.41 in the probiotic arm versus increased by 0.39 in placebo arm (P=0.04).
• Urinary symptoms improved similarly in both treatment arms, with International Prostate Symptom Score showing significant benefit from phytochemicals but no additional probiotic effect on urinary or erectile function measures.
• Safety profile remained excellent with no adverse biochemical changes in liver function, renal parameters, or electrolytes throughout the 4-month intervention period in either treatment arm.
• Formulation specificity limits generalizability, as benefits apply to this particular six-food phytochemical blend and specific five-strain Lactobacillus probiotic (10 billion CFUs with inulin and cholecalciferol).

🎯 Clinical Practice Impact

• Patient Communication: Counsel appropriate active surveillance candidates that evidence-based dietary supplementation may slow PSA progression, emphasizing these are specific formulations tested in clinical trials, not general supplements or dietary changes.
• Practice Integration: Consider discussing phytochemical and probiotic supplementation as adjunctive strategies for men struggling with active surveillance anxiety or showing borderline PSA trends that approach intervention thresholds.
• Risk Management: Avoid recommending untested supplement combinations or extrapolating findings to other nutraceuticals without clinical validation. Document that dietary interventions complement but do not replace standard active surveillance protocols including regular PSA monitoring and repeat biopsies.
• Multidisciplinary Collaboration: Coordinate with nutrition services or integrative medicine specialists who can guide patients toward evidence-based supplement selection and monitor for potential interactions with other medications or conditions.

More on Prostate Cancer